JP2022539238A - ウイルスベクター療法 - Google Patents

ウイルスベクター療法 Download PDF

Info

Publication number
JP2022539238A
JP2022539238A JP2022500019A JP2022500019A JP2022539238A JP 2022539238 A JP2022539238 A JP 2022539238A JP 2022500019 A JP2022500019 A JP 2022500019A JP 2022500019 A JP2022500019 A JP 2022500019A JP 2022539238 A JP2022539238 A JP 2022539238A
Authority
JP
Japan
Prior art keywords
gene therapy
compstatin
subject
moieties
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022500019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539238A5 (cg-RX-API-DMAC7.html
Inventor
フランソワ,セドリック
シャイブラー,ルーカス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of JP2022539238A publication Critical patent/JP2022539238A/ja
Publication of JP2022539238A5 publication Critical patent/JP2022539238A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022500019A 2019-07-05 2020-07-02 ウイルスベクター療法 Pending JP2022539238A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962871058P 2019-07-05 2019-07-05
US62/871,058 2019-07-05
US201962871700P 2019-07-08 2019-07-08
US62/871,700 2019-07-08
US201962875925P 2019-07-18 2019-07-18
US62/875,925 2019-07-18
US201962935569P 2019-11-14 2019-11-14
US62/935,569 2019-11-14
PCT/US2020/040741 WO2021007111A1 (en) 2019-07-05 2020-07-02 Viral vector therapy

Publications (2)

Publication Number Publication Date
JP2022539238A true JP2022539238A (ja) 2022-09-07
JP2022539238A5 JP2022539238A5 (cg-RX-API-DMAC7.html) 2024-03-25

Family

ID=74114222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500019A Pending JP2022539238A (ja) 2019-07-05 2020-07-02 ウイルスベクター療法

Country Status (6)

Country Link
US (1) US20220249706A1 (cg-RX-API-DMAC7.html)
EP (1) EP3996744A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022539238A (cg-RX-API-DMAC7.html)
AU (1) AU2020311330A1 (cg-RX-API-DMAC7.html)
CA (1) CA3143257A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021007111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
BR112019020955A2 (pt) * 2017-04-07 2020-05-05 Apellis Pharmaceuticals, Inc. regimes de dosagem e composições e métodos relacionados
JP2021507884A (ja) 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. 投与レジメンならびに関連組成物および方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
MA71435A (fr) * 2021-05-27 2025-04-30 Apellis Pharmaceuticals, Inc. Édition génomique du complément
US20260043046A1 (en) * 2022-03-17 2026-02-12 Adverum Biotechnologies, Inc. Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070459A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. 繰返し投与を伴うベクターの発現を継続させる方法
JP2016505527A (ja) * 2012-11-15 2016-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. 細胞反応性、長時間作用型または標的化コンプスタチン類似体ならびに関係する組成物および方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029033A2 (en) * 1998-11-17 2000-05-25 The General Hospital Corporation A method of genetic vector delivery
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070459A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. 繰返し投与を伴うベクターの発現を継続させる方法
JP2016505527A (ja) * 2012-11-15 2016-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. 細胞反応性、長時間作用型または標的化コンプスタチン類似体ならびに関係する組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOL IMMUNOL, vol. 46, JPN6024026844, 2009, pages 2911 - 2917, ISSN: 0005735443 *

Also Published As

Publication number Publication date
AU2020311330A1 (en) 2022-02-17
CA3143257A1 (en) 2021-01-14
EP3996744A4 (en) 2023-07-12
EP3996744A1 (en) 2022-05-18
US20220249706A1 (en) 2022-08-11
WO2021007111A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
US20220249706A1 (en) Viral vector therapy
US20230009757A1 (en) Combination therapy for c3 inhibition
JP7856428B2 (ja) 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
JP7077404B2 (ja) Rna治療薬を含むエクソソーム
US20250002910A1 (en) Treatment of complement-mediated disorders
JP7065772B2 (ja) 低反復性ヌクレオチド配列を有する、プロリンおよびアラニン残基が豊富な反復性アミノ酸配列をコードする核酸
JP7858722B2 (ja) C3b結合ポリペプチド
JP7576542B2 (ja) 筋標的化複合体およびそれらの使用
JP2021502058A (ja) Rnaを編集するための組成物および方法
US20230095695A1 (en) Rnas for complement inhibition
KR20170116055A (ko) 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
KR102549520B1 (ko) 비염증성 식세포작용 유도 활성을 갖는 융합분자
US20250075209A1 (en) Rnas for complement inhibition
US20220280598A1 (en) Complement inhibitor dosing regimens
US12251395B2 (en) RNAS for complement inhibition
TW202309279A (zh) 用於補體抑制之rna
Enhancer-Blocking RNA ViRus VectoRs
HK40014102A (en) Combination therapy for c3 inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717